19 research outputs found
Inter-Laboratory Robustness of Next-Generation Bile Acid Study in Mice and Humans: International Ring Trial Involving 12 Laboratories
Abstract
Background
The increasing relevance of individual bile acids quantification in biological samples requires analytical standardization to guarantee robustness and reliability of laboratory results. We have organized the first international ring trial, carried out in 12 laboratories, to evaluate the newly developed LC-MS/MS–based test kit for bile acid analysis.
Methods
Each laboratory received a Biocrates® Bile Acids Kit including system suitability test (SST) protocol. The kit is designed to analyze 16 individual human and 19 mouse bile acids. A set of 9 human and mouse plasma samples was measured in replicates. Laboratories were first required to pass the acceptance criteria for the SST. Within the subset of laboratories passing SST criteria, we evaluated how many laboratories met the target criteria of 80% of reported values with a relative accuracy within the 70%–130% range and analytical precisions (%CV) below 30%.
Results
A total of 12 of 16 participating laboratories passed the SST as the prerequisite to enter the ring trial. All 12 laboratories were then able to successfully run the kit and ring trial samples. Of the overall reported values, 94% were within 70%–130% relative accuracy range. Mean precision was 8.3% CV. The condition of CV <30% was fulfilled by 99% of the reported values.
Conclusions
The first publically available interlaboratory ring trial for standardized bile acids quantification in human and mouse plasma samples showed very good analytical performance, within acceptance criteria typically applied in the preclinical environment. The kit is therefore suitable for standardized quantitative bile acid analysis and the establishment of reference values
Inventory of current EU paediatric vision and hearing screening programmes
Background: We examined the diversity in paediatric vision and hearing screening
programmes in Europe.
Methods: Themes relevant for comparison of screening programmes were derived from
literature and used to compile three questionnaires on vision, hearing and public-health
screening. Tests used, professions involved, age and frequency of testing seem to influence
sensitivity, specificity and costs most. Questionnaires were sent to ophthalmologists,
orthoptists, otolaryngologists and audiologists involved in paediatric screening in all EU fullmember,
candidate and associate states. Answers were cross-checked.
Results: Thirty-nine countries participated; 35 have a vision screening programme, 33 a
nation-wide neonatal hearing screening programme. Visual acuity (VA) is measured in 35
countries, in 71% more than once. First measurement of VA varies from three to seven years
of age, but is usually before the age of five. At age three and four picture charts, including Lea
Hyvarinen are used most, in children over four Tumbling-E and Snellen. As first hearing
screening test otoacoustic emission (OAE) is used most in healthy neonates, and auditory
brainstem response (ABR) in premature newborns. The majority of hearing testing
programmes are staged; children are referred after one to four abnormal tests. Vision
screening is performed mostly by paediatricians, ophthalmologists or nurses. Funding is
mostly by health insurance or state. Coverage was reported as >95% in half of countries, but
reporting was often not first-hand.
Conclusion: Largest differences were found in VA charts used (12), professions involved in
vision screening (10), number of hearing screening tests before referral (1-4) and funding
sources (8)
Recommended from our members
Clinical features of cats with aqueous tear deficiency: a retrospective case series of 10 patients (17 eyes).
ObjectivesThe aim of this study was to describe the clinical findings, diagnostic test results and response to therapy of cats with Schirmer tear test 1 (STT-1) values below the reference interval.MethodsThe medical records of three institutions were searched for cats with ocular surface disease and STT-1 values <9 mm/min, confirmed at two or more separate visits.ResultsTen cats (17 eyes) were included. The mean ± SD (range) age and STT-1 values in affected eye(s) were 6.1 ± 5.7 (0.2-16) years and 2.4 ± 3.1 (0-8) mm/min, respectively. Concurrent ocular surface disease was bilateral in 5/10 cats. Clinical signs included conjunctivitis (14/17 eyes), corneal ulceration (6/17 eyes), non-ulcerative keratitis (4/17 eyes), symblepharon (4/17 eyes), eosinophilic keratitis (3/17 eyes), corneal sequestrum (3/17 eyes), corneal fibrosis (2/17 eyes) and meibomitis (2/17 eyes). Management included: topically applied lacrimomimetics, antiviral drugs, corticosteroids or immunomodulatory drugs; orally administered famciclovir; or surgical procedures, in various combinations. Response to therapy (defined as an increase in STT-1 value of ⩾5 mm/min) was transient (seen at a single reassessment) in 65% of eyes and sustained (seen at ⩾2 consecutive reassessments) in 18% of eyes.Conclusions and relevanceClinical features seen in cats with low STT-1 values are described, although the association between aqueous deficiency and the reported ocular changes is unknown at this time. We encourage clinicians to assess the tear film in cats with ocular surface disease, and initiate therapy with lacrimomimetics if STT-1 values are repeatedly below normal. Such information will further define aqueous tear deficiency in cats, providing a better understanding of disease prevalence, pathogenesis and treatment
Recommended from our members
A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
Thrombospondins are natural inhibitors of angiogenesis, tumor metastases, and tumor growth (melanoma). ABT-510 is a synthetic analog of thrombospondin-1, well tolerated in phase I studies. We conducted a phase II trial evaluating the clinical efficacy of ABT-510 and its effects on biomarkers of angiogenesis and immunity in patients with metastatic melanoma (MM).
A 2-stage phase II clinical trial was conducted to assess the clinical efficacy, safety, and pharmacodynamic effects (angiogenesis and immunity) of ABT-510 in patients with stage IV melanoma. The primary endpoint was 18-week treatment failure rate. Patients self-administered 100 mg of ABT-510 subcutaneously twice daily. Blood samples were collected at baseline and every 3 weeks while on therapy. Eligible patients demonstrated measurable disease, good performance status and no evidence of intracranial metastases. Correlative laboratory studies evaluated biomarkers of angiogenesis and immunity.
Twenty-one patients were enrolled. Most patients were stage M1c (71%) and all had prior therapy for MM. Only 3 of the first 20 patients enrolled were progression free and on treatment at 18 weeks resulting in early termination of the study. Decreases in peripheral blood VEGF-A levels and VEGF-C levels, and CD146 and CD34/133 counts relative to pretreatment were detected. Limited changes in antitumor T cell immunity were observed.
ABT-510 therapy administered at 100 mg twice/day in patients with MM did not demonstrate definite clinical efficacy. Further dose escalation or combination with cytotoxic therapy may be more effective therapeutically